2019 Future of Shy-Drager Syndrome R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments
The global demand for Shy-Drager Syndrome treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Shy-Drager Syndrome pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Shy-Drager Syndrome pipeline companies from advancing their products into Phase 3 or Phase 4.
Shy-Drager Syndrome Report Description-
The 2019 pipeline study on Shy-Drager Syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Shy-Drager Syndrome pipeline compounds.
The Shy-Drager Syndrome pipeline guide presents information on all active drugs currently being developed for Shy-Drager Syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Shy-Drager Syndrome pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Shy-Drager Syndrome drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Shy-Drager Syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Shy-Drager Syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Shy-Drager Syndrome pipeline report includes-
Shy-Drager Syndrome Report Description-
The 2019 pipeline study on Shy-Drager Syndrome pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Shy-Drager Syndrome pipeline compounds.
The Shy-Drager Syndrome pipeline guide presents information on all active drugs currently being developed for Shy-Drager Syndrome. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.
Details of current status, R&D progress and latest developments for every Shy-Drager Syndrome pipeline candidate are analyzed.
Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Shy-Drager Syndrome drug candidates.
Drug development companies, collaborators, originating companies, license providers and universities participating in the Shy-Drager Syndrome product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.
The report assists in identifying potential upcoming companies and drugs in Shy-Drager Syndrome pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.
VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.
Scope of Shy-Drager Syndrome pipeline report includes-
- An overview of Shy-Drager Syndrome disease including symptoms, causes, diagnosis and available treatment options is provided.
- Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
- Phase wise count of Shy-Drager Syndrome pipeline
- Company wise list of Shy-Drager Syndrome pipeline
- Mechanism of Action wise Shy-Drager Syndrome pipeline
- For each pipeline candidate, the following details are provided
- Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
- Current status of development
- Drug overview
- Mechanism of Action
- Pre-clinical and Clinical Trials/Results
- Company Overview and Recent Developments
- The report is designed to help industry executives promote the success and continued growth of their organizations
- Get clear understanding of the entire Shy-Drager Syndrome pipeline, with details on active projects
- Stay ahead of the competition through comprehensive knowledge of Shy-Drager Syndrome pipeline progress
- Get in detail information of each product with updated information on each project along with key milestones
- Gain clear insights into companies participating in Shy-Drager Syndrome pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
- Get trial information for each pipeline product under development
- Understand the pipeline structure in terms of mechanism of Action, phase and company
1. TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2. GLOBAL SHY-DRAGER SYNDROME PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Shy-Drager Syndrome Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Shy-Drager Syndrome pipeline, H1- 2019
3.5 Mechanism of Action wise Shy-Drager Syndrome Pipeline Candidates
4 AFFIRIS AG MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
4.1 AFFiRiS AG Business Profile
4.2 AFFiRiS AG Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
5.1 Biohaven Pharmaceutical Holding Company Business Profile
5.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 CORESTEM INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
6.1 Corestem Inc Business Profile
6.2 Corestem Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 DENALI THERAPEUTICS INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
7.1 Denali Therapeutics Inc Business Profile
7.2 Denali Therapeutics Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 ENTERIN INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
8.1 Enterin Inc Business Profile
8.2 Enterin Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 ICB INTERNATIONAL INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
9.1 ICB International Inc Business Profile
9.2 ICB International Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 INHIBIKASE THERAPEUTICS MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
10.1 Inhibikase Therapeutics Business Profile
10.2 Inhibikase Therapeutics Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 MITODYS THERAPEUTICS LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
11.1 MitoDys Therapeutics Ltd Business Profile
11.2 MitoDys Therapeutics Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 MODAG GMBH MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
12.1 Modag GmbH Business Profile
12.2 Modag GmbH Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 NEUROPORE THERAPIES INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
13.1 Neuropore Therapies Inc Business Profile
13.2 Neuropore Therapies Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 PRANA BIOTECHNOLOGY LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
14.1 Prana Biotechnology Ltd Business Profile
14.2 Prana Biotechnology Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 UNITED NEUROSCIENCE INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
15.1 United Neuroscience Inc Business Profile
15.2 United Neuroscience Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. LATEST SHY-DRAGER SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019
17. APPENDIX
17.1 About Us
17.2 Sources and Methodology
17.3 Contact Information
1.1 List of Tables
1.2 List of Figures
2. GLOBAL SHY-DRAGER SYNDROME PIPELINE OVERVIEW
2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology
3. EXECUTIVE SUMMARY
3.1 Shy-Drager Syndrome Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
3.2.1 Pre-clinical
3.2.2 Discovery
3.2.3 Phase
3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
3.3.1 Phase
3.3.2 Pre-registration
3.4 Companies involved in Shy-Drager Syndrome pipeline, H1- 2019
3.5 Mechanism of Action wise Shy-Drager Syndrome Pipeline Candidates
4 AFFIRIS AG MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
4.1 AFFiRiS AG Business Profile
4.2 AFFiRiS AG Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
4.3 Drug Snapshot
4.3.1 Originator
4.3.2 Collaborator/Co-Developer
4.3.3 Route of Administration
4.3.4 Orphan Drug/Fast Track/Special Designation
4.3.5 Geography
4.3.6 Type of Molecular Entity
4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments
5 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
5.1 Biohaven Pharmaceutical Holding Company Business Profile
5.2 Biohaven Pharmaceutical Holding Company Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
5.3 Drug Snapshot
5.3.1 Originator
5.3.2 Collaborator/Co-Developer
5.3.3 Route of Administration
5.3.4 Orphan Drug/Fast Track/Special Designation
5.3.5 Geography
5.3.6 Type of Molecular Entity
5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments
6 CORESTEM INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
6.1 Corestem Inc Business Profile
6.2 Corestem Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
6.3 Drug Snapshot
6.3.1 Originator
6.3.2 Collaborator/Co-Developer
6.3.3 Route of Administration
6.3.4 Orphan Drug/Fast Track/Special Designation
6.3.5 Geography
6.3.6 Type of Molecular Entity
6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments
7 DENALI THERAPEUTICS INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
7.1 Denali Therapeutics Inc Business Profile
7.2 Denali Therapeutics Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
7.3 Drug Snapshot
7.3.1 Originator
7.3.2 Collaborator/Co-Developer
7.3.3 Route of Administration
7.3.4 Orphan Drug/Fast Track/Special Designation
7.3.5 Geography
7.3.6 Type of Molecular Entity
7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments
8 ENTERIN INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
8.1 Enterin Inc Business Profile
8.2 Enterin Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
8.3 Drug Snapshot
8.3.1 Originator
8.3.2 Collaborator/Co-Developer
8.3.3 Route of Administration
8.3.4 Orphan Drug/Fast Track/Special Designation
8.3.5 Geography
8.3.6 Type of Molecular Entity
8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments
9 ICB INTERNATIONAL INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
9.1 ICB International Inc Business Profile
9.2 ICB International Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
9.3 Drug Snapshot
9.3.1 Originator
9.3.2 Collaborator/Co-Developer
9.3.3 Route of Administration
9.3.4 Orphan Drug/Fast Track/Special Designation
9.3.5 Geography
9.3.6 Type of Molecular Entity
9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments
10 INHIBIKASE THERAPEUTICS MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
10.1 Inhibikase Therapeutics Business Profile
10.2 Inhibikase Therapeutics Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
10.3 Drug Snapshot
10.3.1 Originator
10.3.2 Collaborator/Co-Developer
10.3.3 Route of Administration
10.3.4 Orphan Drug/Fast Track/Special Designation
10.3.5 Geography
10.3.6 Type of Molecular Entity
10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments
11 MITODYS THERAPEUTICS LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
11.1 MitoDys Therapeutics Ltd Business Profile
11.2 MitoDys Therapeutics Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
11.3 Drug Snapshot
11.3.1 Originator
11.3.2 Collaborator/Co-Developer
11.3.3 Route of Administration
11.3.4 Orphan Drug/Fast Track/Special Designation
11.3.5 Geography
11.3.6 Type of Molecular Entity
11.3.7 Current Status
11.4 Drug Overview
11.5 Drug Mechanism of Action
11.6 Clinical/Pre-clinical Trial Details
11.7 Latest Drug Developments
12 MODAG GMBH MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
12.1 Modag GmbH Business Profile
12.2 Modag GmbH Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
12.3 Drug Snapshot
12.3.1 Originator
12.3.2 Collaborator/Co-Developer
12.3.3 Route of Administration
12.3.4 Orphan Drug/Fast Track/Special Designation
12.3.5 Geography
12.3.6 Type of Molecular Entity
12.3.7 Current Status
12.4 Drug Overview
12.5 Drug Mechanism of Action
12.6 Clinical/Pre-clinical Trial Details
12.7 Latest Drug Developments
13 NEUROPORE THERAPIES INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
13.1 Neuropore Therapies Inc Business Profile
13.2 Neuropore Therapies Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
13.3 Drug Snapshot
13.3.1 Originator
13.3.2 Collaborator/Co-Developer
13.3.3 Route of Administration
13.3.4 Orphan Drug/Fast Track/Special Designation
13.3.5 Geography
13.3.6 Type of Molecular Entity
13.3.7 Current Status
13.4 Drug Overview
13.5 Drug Mechanism of Action
13.6 Clinical/Pre-clinical Trial Details
13.7 Latest Drug Developments
14 PRANA BIOTECHNOLOGY LTD MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
14.1 Prana Biotechnology Ltd Business Profile
14.2 Prana Biotechnology Ltd Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
14.3 Drug Snapshot
14.3.1 Originator
14.3.2 Collaborator/Co-Developer
14.3.3 Route of Administration
14.3.4 Orphan Drug/Fast Track/Special Designation
14.3.5 Geography
14.3.6 Type of Molecular Entity
14.3.7 Current Status
14.4 Drug Overview
14.5 Drug Mechanism of Action
14.6 Clinical/Pre-clinical Trial Details
14.7 Latest Drug Developments
15 UNITED NEUROSCIENCE INC MULTIPLE SYSTEM ATROPHY (MSA)/SHY-DRAGER SYNDROME PIPELINE DETAILS
15.1 United Neuroscience Inc Business Profile
15.2 United Neuroscience Inc Multiple System Atrophy (MSA)/Shy-Drager Syndrome Drug Details
15.3 Drug Snapshot
15.3.1 Originator
15.3.2 Collaborator/Co-Developer
15.3.3 Route of Administration
15.3.4 Orphan Drug/Fast Track/Special Designation
15.3.5 Geography
15.3.6 Type of Molecular Entity
15.3.7 Current Status
15.4 Drug Overview
15.5 Drug Mechanism of Action
15.6 Clinical/Pre-clinical Trial Details
15.7 Latest Drug Developments
16. LATEST SHY-DRAGER SYNDROME DRUG PIPELINE DEVELOPMENTS, 2019
17. APPENDIX
17.1 About Us
17.2 Sources and Methodology
17.3 Contact Information
